Skip to main content

Table 2 DFS and OS events stratified by different groups

From: Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

  Overall
n = 3761 (%)
HER2-neg
n = 3313 (%)
HER2-pos-T
n= 448 (%)
DFS events    
No recurrence 3318 (88.2) 2911 (87.9) 407 (90.8)
Local-regional recurrence 73 (1.9) 63 (1.9) 10 (2.2)
Contralateral breast cancer 38 (1.0) 36 (1.0) 2 (0.5)
Second non-breast malignancy 56 (1.5) 52 (1.6) 4 (1.0)
Distant recurrence 198 (5.3) 179 (5.4) 19 (4.2)
Death without recurrence 78 (2.1) 72 (2.2) 6 (1.3)
OS events    
Alive 3570 (94.9) 3136 (94.7) 434 (96.9)
Death of any cause 191 (5.1) 177 (5.3) 14 (3.1)
Death with recurrence 123 (3.0) 105 (3.1) 8 (1.8)
Death without recurrence 78 (2.1) 72 (2.2) 6 (1.3)
  1. HER2, human epidermal growth factor receptor 2; DFS, disease-free survival; OS, overall survival